Health Care • Biotechnology: Pharmaceutical Preparations
$7.51 ▼ -0.28
(-3.66%)
MKT CAP: $106.4M • VOL: 244.4K
52W L $5 52W H $17
ROARABLE / RQD
D- • 38/100
PIOTROSKI
2 / 9
IMUX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$103.2M | -$98.1M | -$99.2M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$97.2M | -$100.5M | -$93.6M |
| EBITDA (Normalized) | -$103.1M | -$97.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$85.8M | -$84.8M | -$70.8M |
| Capital Expenditures (CapEx) | $161.0K | $264.0K | — |
| Free Cash Flow (FCF) | -$86.0M | -$85.0M | -$70.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $15.5M | $35.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$6.7M | $18.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IMUX.